Literature DB >> 19493316

Use of liposomes as drug delivery vehicles for treatment of melanoma.

Melissa A Tran1, Rebecca J Watts, Gavin P Robertson.   

Abstract

Melanoma is a progressive disease that claims many lives each year due to lack of therapeutics effective for the long-term treatment of patients. Currently, the best treatment option is early detection followed by surgical removal. Better melanoma therapies that are effectively delivered to tumors with minimal toxicity for patients are urgently needed. Nanotechnologies provide one approach to encapsulate therapeutic agents leading to improvements in circulation time, enhanced tumor uptake, avoidance of the reticulo-endothelial system, and minimization of toxicity. Liposomes in particular are a promising nanotechnology that can be used for more effective delivery of therapeutic agents to treat melanoma. Liposomes delivering chemotherapies, siRNA, asODNs, DNA, and radioactive particles are just some of the promising new nanotechnology based therapies under development for the treatment of melanoma that are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19493316      PMCID: PMC2770731          DOI: 10.1111/j.1755-148X.2009.00581.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  128 in total

Review 1.  The mammary gland: a model for development.

Authors:  C W Daniel; G H Smith
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

Review 2.  Transferrin As A targeting ligand for liposomes and anticancer drugs.

Authors:  M Singh
Journal:  Curr Pharm Des       Date:  1999-06       Impact factor: 3.116

Review 3.  Tumor progression, early diagnosis and prognosis of melanoma.

Authors:  D Elder
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

4.  Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.

Authors:  J A Ellerhorst; A Bedikian; S Ring; A C Buzaid; O Eton; S S Legha
Journal:  Oncol Rep       Date:  1999 Sep-Oct       Impact factor: 3.906

5.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.

Authors:  L del Peso; M González-García; C Page; R Herrera; G Nuñez
Journal:  Science       Date:  1997-10-24       Impact factor: 47.728

6.  Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells.

Authors:  A Petri-Fink; M Chastellain; L Juillerat-Jeanneret; A Ferrari; H Hofmann
Journal:  Biomaterials       Date:  2005-05       Impact factor: 12.479

Review 7.  Melanoma and sun exposure: an overview of published studies.

Authors:  J M Elwood; J Jopson
Journal:  Int J Cancer       Date:  1997-10-09       Impact factor: 7.396

8.  Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer.

Authors:  Junichi Yano; Kazuko Hirabayashi; Shin-Ichiro Nakagawa; Tohru Yamaguchi; Masaki Nogawa; Isao Kashimori; Haruna Naito; Hidetoshi Kitagawa; Kouichi Ishiyama; Tadaaki Ohgi; Tatsuro Irimura
Journal:  Clin Cancer Res       Date:  2004-11-15       Impact factor: 12.531

Review 9.  Signal transduction of stress via ceramide.

Authors:  S Mathias; L A Peña; R N Kolesnick
Journal:  Biochem J       Date:  1998-11-01       Impact factor: 3.857

10.  Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy.

Authors:  L M Mir; L F Glass; G Sersa; J Teissié; C Domenge; D Miklavcic; M J Jaroszeski; S Orlowski; D S Reintgen; Z Rudolf; M Belehradek; R Gilbert; M P Rols; J Belehradek; J M Bachaud; R DeConti; B Stabuc; M Cemazar; P Coninx; R Heller
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more
  22 in total

Review 1.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

2.  Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment.

Authors:  Raghavendra Gowda; Saketh S Dinavahi; Soumya Iyer; Shubhadeep Banerjee; Rogerio I Neves; Colette R Pameijer; Gavin P Robertson
Journal:  Nanomedicine       Date:  2018-01-06       Impact factor: 5.307

Review 3.  Engineering nanomedicines for improved melanoma therapy: progress and promises.

Authors:  Di Bei; Jianing Meng; Bi-Botti C Youan
Journal:  Nanomedicine (Lond)       Date:  2010-11       Impact factor: 5.307

Review 4.  Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems.

Authors:  Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-11-19       Impact factor: 4.481

Review 5.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

6.  Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials.

Authors:  P Severino; J F Fangueiro; S V Ferreira; R Basso; M V Chaud; M H A Santana; A Rosmaninho; E B Souto
Journal:  Clin Transl Oncol       Date:  2013-01-24       Impact factor: 3.405

7.  Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.

Authors:  Raghavendra Gowda; SubbaRao V Madhunapantula; Arati Sharma; Omer F Kuzu; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2014-07-31       Impact factor: 6.261

8.  Neutral polymeric micelles for RNA delivery.

Authors:  Brittany B Lundy; Anthony Convertine; Martina Miteva; Patrick S Stayton
Journal:  Bioconjug Chem       Date:  2013-02-22       Impact factor: 4.774

Review 9.  Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.

Authors:  Javed Ahmad; Sohail Akhter; Nigel H Greig; Mohammad Amjad Kamal; Patrick Midoux; Chantal Pichon
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 10.  Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment.

Authors:  Jafrin Jobayer Sonju; Achyut Dahal; Sitanshu S Singh; Seetharama D Jois
Journal:  J Control Release       Date:  2020-10-01       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.